** Shares of cancer drug developer CG Oncology fall 4.8% to $32.09 premarket
** CGON unveils proposed public offering wherein the late-stage drug developer along with an existing shareholder plans to sell shares
** Co is offering 7.3 mln shares, while investment firm ORI Capital is selling 700,000 shares in the proposed offering
** CGON's experimental immunotherapy has shown promise in bladder cancer, researchers reported last week
** Co plans to use the proceeds to fund the development of its experimental immunotherapy
** Morgan Stanley, Goldman Sachs, TD Cowen and Stifel are the joint book-running managers for the offering
** Co has 67.6 mln outstanding shares and $2.28 bln market capitalization - LSEG data
** CGON debuted on the Nasdaq in January after an upsized $380 mln offering at $19 IPO price
** As of last close, CGON shares up 77.4% since debut on Jan. 25
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.